

Inhaler Devices

A range of inhaled drugs, both bronchodilators and inhaled corticosteroids (reliever and controller/preventer drugs respectively) are licensed for use in the United Kingdom.

Traditionally, inhaler devices are classified as follows:

- i) Pressurised Metered Dose Inhalers (pMDIs)*
 - Press and breathe inhalers
 - Breath actuated inhalers
 - pMDI used in combination with small and large volume spacer devices
- ii) Dry Powder inhalers (DPIs)**
 - Single dose inhalers
 - Multidose inhalers
- iii) Nebulisers (not dealt with in this opinion sheet)

Given the evidence on the difficulty and varying ability of patients and health professionals in mastering inhaler technique, a more practical classification¹ could divide inhalers into 'Patient Inhalation-Independent' Aerosol Devices (those marked with * and the Soft Mist Inhalers e.g. the Respimat) and 'Patient Inhalation-Dependent' Aerosol Device (marked with **)

For inhaled medication to reach the airways:

- i) The drug needs to be delivered from an inhaler device in a format suitable for inhalation and deposition in the lungs; and
- ii) The person taking the medication must be able to use the inhaler device effectively.

The least cost effective inhaler device is the one that patients cannot use. In deciding which device and drug formulation to prescribe, determine the patient's ability to use the prescribed device correctly

Many people cannot use inhalers optimally, particularly in the case of pMDIs.¹⁻⁶ Therefore, specific instructions for each device are necessary.

Inhaler use assessment checklist

- Able to prepare the device for use?
- Adopts correct posture?
- Exhales fully (away from device) before use?
- Demonstrates appropriate effort and duration of inhalation for the particular device? Holds breath for 10 seconds after inhalation?

Checking inhaler technique

While the general method for using each group of inhaler devices is similar (slow inhalation for pMDIs, and forceful for DPIs), clinicians should familiarise themselves with the features and instructions on the manufacturer's Summary of Product Characteristics (SPC) and patient information leaflet (PIL) for each device/drug prescribed.⁷ When prescribing a new inhaler, or reviewing patients' progress, inhaler technique should be demonstrated by the clinician, followed by the patient. Many people forget how to use their inhaler devices, and this is likely to affect clinical outcomes.^{1,8,9}

The patient's ability to inhale at the appropriate rate for a device can be assessed by using the In-Check[®] device. There are a range of teaching aids available including the Vitalograph AIM[®] machine or the 2 Tone[®] Trainer for the pMDI^{10,11} and the Mag-flo[®] for DPIs.

Inhaler device characteristics

The term 'aerosol' is broadly applied to any suspension of solid or liquid particles in a gas, usually air. Particle diameters may range from about 0.001 to about 100 micrometres.

Two key factors influence what proportion of the dose will reach the lungs:

- Size: large particles will be deposited in the mouth and throat; very small ones (under 0.5 microns¹²) will be exhaled without ever getting to the airways.
- Speed: inhaling too fast through any inhaler results in greater unwanted deposition in the upper airways.

An important characteristic of all inhaler devices is its internal resistance. Devices such as spacers and pMDIs have a low internal resistance that allows air to flow through them with very little difficulty. Other devices, such as some of the DPIs, have a high internal resistance.

To maximise lung deposition and minimise upper airway loss, the patient should be encouraged to inhale with appropriate effort for the resistance of each device. For example, the low-resistance pMDI requires a slow inhalation speed – so the patient should be encouraged to inhale very gently. High-resistance DPIs deliver more drug to the lungs at faster respiratory flows – so a strong and forceful inhalation should be encouraged.

The change from CFC propellants to HFA formulations in pMDIs and breath-activated (BA) pMDIs raises several issues. Some HFA formulation products produce ultra-fine aerosol particles, resulting in greater lung deposition and less oropharyngeal deposition. Therefore, all beclometasone inhalers must be prescribed by brand name as a lower dose is required in the case of Qvar[®] (CFC-Free BDP) and Fostair[®] (CFC-Free BDP and formoterol fumarate dihydrate).

Some pMDI formulations include alcohol, and this is clearly important when prescribing for patients not wishing to ingest alcohol.¹³

Using a pMDI

As the emitted drug is delivered over just a fraction of a second, it is important that the patient starts inhaling **slowly, before** actuating the device. Inhalation rate is ideally around 30 litres per minute. Patients should be instructed to wait 30 seconds between doses if they need to use their pMDI or BA pMDI twice. Most guidelines suggest the use of a spacer device where patients are unable to co-ordinate the use of a pMDI; this removes some of the larger particles, reduces the need for perfect timing, and reduces potential side effects by reduced drug deposition in the throat.

pMDI inhalation technique (read the PIL for each device)

- Remove cap and check mouthpiece is clear
- Shake inhaler and exhale fully
- Place inhaler in mouth, grip gently between teeth, and seal lips around it
- Start breathing in very slowly and deeply
- Then, just after starting to inhale, press the canister
- Continue to breathe in slowly and deeply
- Hold your breath for 10 seconds
- Then exhale and place the cap back onto the inhaler device

Breath actuated pMDIs

Similar in many respects to a standard pMDI, these are helpful for patients unable to co-ordinate pressing the canister with inhalation. Release of aerosol from these devices only occurs when the patient achieves a minimum inspiratory flow rate through the mouthpiece (set at, or about, the ideal speed of inhalation for a pMDI). This device also ensures the patient starts breathing before drug is released.

- Autohaler
- Easibreathe

Soft Mist inhalers (SMIs)

Introduced in 2007, these devices use stored mechanical energy to force a solution of drug through two fine nozzles, creating a slow moving aerosol. Like the pMDI, the patient needs to co-ordinate inhaling and actuating the device, and as the aerosol duration is approximately 1.5 seconds, a slow inhalation technique is very important. The internal resistance of this device is low, so patients must be encouraged to inhale very gently.

- RespiMat

Using a Dry Powder device

Drug emission from a dry powder device is wholly dependent on the inspiratory flow rate generated by the patient. Therefore, a forceful inspiration is needed in order to ensure drug de-aggregation into respirable particles, to ensure release of the full measured dose, and to achieve

good lung deposition.

Lactose is frequently added to dry powder formulations to improve aerosolisation - and this reduces the energy required for de-aggregation. Some patients can taste the lactose.

DPI inhalation technique (read the PIL for each device)

- Prepare device according to manufacturers instructions
- Exhale fully (not into the inhaler)
- Place inhaler in mouth, grip gently between teeth, and seal lips around it
- From the beginning, inhale forcefully and deeply until your lungs are full
- Hold your breath for 10 seconds
- Then exhale and place the cap or cover back onto the inhaler device

Breath-Actuated Dry Powder Inhalers (DPI):

Inhaling through a DPI requires a forceful inspiration in order to ensure de-aggregation into respirable particles. For example, the Novoliser® only releases drug when the inspiratory flow rate is sufficient to ensure good de-aggregation occurs.

Dry Powder Aerosol Devices (DPis)

- Accuhaler
- Aerohaler
- Aeroliser
- Clickhaler
- Cyclohaler
- Diskhaler
- Easyhaler
- HandiHaler
- Pulvinal
- Spinhaler
- Turbohaler
- Twisthaler

Breath Actuated Dry Powder Device

- Novolizer

The emitted dose of drug is different to the nominal dose on the package and this in turn is different to the dose which reaches the lungs; the latter is very dependent upon the device/drug/patient interaction.

Useful Resource: ADMIT website:

<http://www.admit-online.info/>

References:

1. Bell, J. Why Optimise Inhaler Technique in Asthma and COPD? *Brit. J. Prim. Care Nursing* 2008;**2(2)**:37-9
2. Virchow JC, Crompton GK, Dal Negro R, *et al.* Importance of inhaler devices in the management of airway disease. *Respir Med* 2008;**102(1)**:10-19.
3. Crompton GK, Barnes PJ, Broeders M, *et al.* The need to improve inhalation technique in Europe: A report from the Aerosol Drug Management Improvement Team. *Respir Med* 2006;**100(9)**:1479-94.
4. Crompton GK. Problems patients have using pressurized aerosol inhalers. *European Journal of Respiratory Diseases* 1982;**63(Suppl. 119)**:101-4.
5. Crompton GK. The adult patient's difficulties with inhalers. *Lung* 1990;**168 (suppl)**:658-62.
6. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices: Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. *Chest* 1994;**105(1)**:111-16.
7. Datapharm Communications Ltd 2007. Electronic Medicines Compendium (the eMC).) . 2008 [cited 2008 Apr. 24]; Available from: URL:<http://emc.medicines.org.uk/>
8. Have WHOT, Van De Berg NJ, Bindels PJE, Van Aalderen WMC, van der Palen J. Assessment of inhalation technique in children in general practice: Increased risk of incorrect performance with new device. *J Asthma* 2008; **45(1)**:67-71.
9. Lavorini F, Magnan A, Christophe Dubus J, *et al.* Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respir Med* 2008;**102(4)**:593-604.
10. Al-Showair RAM, Pearson SB, Chrystyn H. The potential of a 2Tone trainer to help patients use their metered-dose inhalers. *Chest* 2007;**131(6)**:1776-82.
11. Sarvis CA, Tice AL, Plake KS. Evaluation of inhaler technique using the aerosol inhalation monitor. *Journal of Pharmacy Practice* 2004;**17(4)**:275-79.
12. Leach, C.L., Davidson, P.J., Boudreau, R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. *ERJ* 1998;**12(6)**:1346-1353.
13. Alrasbia, Maryam, Sheikh A. Alcohol-based pressurised metered-dose inhalers for use in asthma: a descriptive study. *Prim Care Resp J* 2008;**17(2)**:111-13.

Date of Preparation: August 2008

Authors: Dr Mark L Levy and Linda Pearce

Editor: Dr Paul Stephenson, GPIAG

This series of opinion sheets has been sponsored by educational grants from AstraZeneca UK Limited, Boehringer-Ingelheim Ltd/Pfizer Ltd, Schering Plough Ltd and Teva UK Ltd. The sponsors may have reviewed this opinion sheet to advise on matters of factual accuracy related to their product licence but they have not contributed to, nor have they influenced, the contents of this opinion sheet. The views expressed in this publication are not necessarily those of either the sponsors or the General Practice Airways Group (GPIAG).

©GPIAG. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the prior permission of the GPIAG. The GPIAG is a registered charity (Charity Number: 1098117) and a company limited by guarantee (Company number 4298947). Registered Offices: 2 Wellington Place, Leeds, LS1 4AP

Address for Correspondence: GPIAG, Smithy House, Waterbeck, Lockerbie, DG11 3EY, UK

Telephone: +44 (0)1461 600639 **Facsimile:** +44 (0)1361 331811 **Email:** info@gpiag.org **Websites:** <http://www.gpiag.org>, <http://www.thepcrj.org>